US EditionInvestor Alert: Robbins LLP Informs Investors of the Novo Nordisk A/S Class Action Lawsuit - Novo Nordisk (NYSE:NVO)
UNITED STATES, AUG 4 – Investors allege Novo Nordisk overstated 2025 growth due to unreported risks from compounded GLP-1s and competition, causing a stock drop of nearly 22%, lawsuit claims.
- Robbins LLP informed investors on August 5, 2025, about a class action lawsuit filed on behalf of Novo Nordisk A/S shareholders.
- The lawsuit was filed after Novo Nordisk revised its revenue and earnings forecasts downward on July 29, 2025, citing increased competition and challenging market conditions.
- Following the announcement, Novo Nordisk's stock price fell sharply from $69.00 on July 28 to $53.94 on July 29, a 21.83% decline in one day.
- Shareholders who acquired Novo Nordisk securities between May 7 and July 28, 2025, may join the class action and must file lead plaintiff papers by September 30, 2025.
- The litigation aims to recover investor losses due to alleged securities fraud for overstating growth potential and misrepresenting market penetration of GLP-1 products.
30 Articles
30 Articles
LoudounTimes.com
Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
PHILADELPHIA, Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, after a class action lawsuit was…
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT – Investors With Large Losses in Novo Nordisk A/S ...
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Novo Nordisk A/S (“Novo” or…
After last week's shocking forecast cut, Novo Nordisk will take cost measures, outgoing CEO Lars Fruergaard Jørgensen said in the pharmaceutical giant's report. The stock is trading shakily in early trading.
This could very well end in layoffs at the Danish pharmaceutical giant, estimates economic correspondent Casper Schrøder.
Coverage Details
Bias Distribution
- 71% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
